Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: A retrospective cohort study utilizing the Cubicin® Outcomes Registry and Experience

Clinical Therapeutics

Volumn 31, Issue 9, 2009, Pages 1936-1945

  Sakoulas, George ^a,b   Brown, Jack ^c   Lamp, Kenneth C ^c   Friedrich, Lawrence V ^c   Lindfield, Kimberly C ^c  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

antibiotics; daptomycin; first line therapy; Staphylococcus aureus

Indexed keywords

DAPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIUM CULTURE; CHILD; COHORT ANALYSIS; DIABETES MELLITUS; ENDOCARDITIS; FEMALE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; REGISTER; SCHOOL CHILD; SKIN INFECTION; SKIN STRUCTURE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; CHILD; COHORT STUDIES; DAPTOMYCIN; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72149101592     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.09.012     Document Type: Article

References (34)

1. Styers D., Sheehan D.J., Hogan P., and Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 Status in the United States. Ann Clin Microbiol Antimicrob 5 (2006) 2
2. Cosgrove S.E., Qi Y., Kaye K.S., et al. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26 (2005) 166-174
3. Lodise Jr. T.P., and McKinnon P.S. Burden of methicillin-resistant Staphylococcus aureus: Focus on clinical and economic outcomes. Pharmacotherapy 27 (2007) 1001-1012
4. Shurland S., Zhan M., Bradham D.D., and Roghmann M.C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 28 (2007) 273-279
5. Blot S.I., Vandewoude K.H., Hoste E.A., and Colardyn F.A. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillinsusceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 162 (2002) 2229-2235
6. Kaech C., Elzi L., Sendi P., et al. Course and outcome of Staphylococcus aureus bacteraemia: A retrospective analysis of 308 episodes in a Swiss tertiary-care centre. Clin Microbiol Infect. 12 (2006) 345-352
7. Gómez J., García-Vázquez E., Baños R., et al. Predictors of mortality in patients with methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia: The role of empiric antibiotic therapy. Eur J Clin Microbiol Infect Dis. 26 (2007) 239-245
8. Deal E.N., Micek S.T., Ritchie D.J., et al. Predictors of in-hospital mortality for bloodstream infections caused by Enterobacter species or Citrobacter freundii. Pharmacotherapy 27 (2007) 191-199
9. French G.L. Bactericidal agents in the treatment of MRSA infections-the potential role of daptomycin. J Antimicrob Chemother 58 (2006) 1107-1117
10. Kanafani Z.A., and Corey G.R. Daptomycin: A rapidly bactericidal lipopeptide for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther. 5 (2007) 177-184
11. Cubicin (daptomycin for injection) [package insert] (2006), Cubist Pharmaceuticals, Inc, Lexington, Mass. http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archived=1880 Accessed September 5, 2009
12. Rolston K.V., Segreti J., Lamp K.C., and Friedrich L.V. Cubicin Outcomes Registry and Experience (CORE) methodology. Am J Med. 120 Suppl 1 (2007) S4-S5
13. Sakoulas G., Golan Y., Lamp K.C., et al. Daptomycin in the treatment of bacteremia. Am J Med. 120 Suppl 1 (2007) S21-S27
14. Lamp K.C., Friedrich L.V., Mendez-Vigo L., and Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 120 Suppl 1 (2007) S13-S20
15. Owens Jr. R.C., Lamp K.C., Friedrich L.V., and Russo R. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med. 120 Suppl 1 (2007) S6-S12
16. Levine D.P., and Lamp K.C. Daptomycin in the treatment of patients with infective endocarditis: Experience from a registry. Am J Med. 120 Suppl 1 (2007) S28-S33
17. Hosmer D.W., and Lemeshow S. Applied Logistic Regression. 2nd ed. (2000), Wiley, New York, NY
18. Draper N.R., and Smith H. Applied Regression Analysis. 2nd ed. (1981), Wiley, New York, NY
19. Fowler Jr. V.G., Boucher H.W., Corey G.R., et al., S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 355 (2006) 653-665
20. Aksoy O., Sexton D.J., Wang A., et al. Early surgery in patients with infective endocarditis: A propensity score analysis. Clin Infect Dis. 44 (2007) 364-372
21. Engemann J.J., Friedman J.Y., Reed S.D., et al. Clinical outcomes and costs due to Staphylococcus aureus bacteremia among patients receiving longterm hemodialysis. Infect Control Hosp Epidemiol 26 (2005) 534-539
22. Nissenson A.R., Dylan M.L., Griffiths R.I., et al. Clinical and economic outcomes of Staphylococcus aureus septicemia in ESRD patients receiving hemodialysis. Am J Kidney Dis. 46 (2005) 301-308
23. Spies C., Madison J.R., and Schatz I.J. Infective endocarditis in patients with end-stage renal disease: Clinical presentation and outcome. Arch Intern Med. 164 (2004) 71-75
24. Garrouste-Orgeas M., Chevret S., Mainardi J.L., et al. A one-year prospective study of nosocomial bacteraemia in ICU and non-ICU patients and its impact on patient outcome. J Hosp Infect. 44 (2000) 206-213
25. Laupland K.B., Ross T., and Gregson D.B. Staphylococcus aureus bloodstream infections: Risk factors, outcomes, and the influence of methicillin resistance in Calgary, Canada, 2000-2006. J Infect Dis. 198 (2008) 336-343
26. Stoeckle M., Kaech C., Trampuz A., and Zimmerli W. The role of diabetes mellitus in patients with bloodstream infections. Swiss Med Wkly. 138 (2008) 512-519
27. Bertoni A.G., Saydah S., and Brancati F.L. Diabetes and the risk of infectionrelated mortality in the U.S. Diabetes Care 24 (2001) 1044-1049
28. Shorr A.F., Kunkel M.J., and Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: Pooled analysis of randomized studies. J Antimicrob Chemother 56 (2005) 923-929
29. Patel J.B., Jevitt L.A., Hageman J., et al. An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus. Clin Infect Dis. 42 (2006) 1652-1653
30. Sakoulas G., Adler J., Thauvin-Eliopoulos C., et al. Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin. Antimicrob Agents Chemother 50 (2006) 1581-1585
31. Cui L., Tominaga E., Neoh H.M., and Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother. 50 (2006) 1079-1082
32. Pillai S.K., Gold H.S., Sakoulas G., et al. Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF. Antimicrob Agents Chemother 51 (2007) 2223-2225
33. Boucher H.W., and Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 45 (2007) 601-608
34. Gould F.K., Brindle R., Chadwick P.R., et al., MRSA Working Party of the British Society for Antimicrobial Chemotherapy. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother 63 (2009) 849-861